Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Ephrin Type B Receptor 4 (EPHB4) Drugs in Development Report Overview
Ephrin type-B receptor 4 is a protein encoded by the EPHB4 gene. The Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) drugs in development research report provides comprehensive information on the therapeutics under development for Ephrin Type B Receptor 4. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.
The pipeline report covers the descriptive pharmacological action and product description of EPHB4. It includes the complete research and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in EPHB4 therapeutic development and features dormant and discontinued products.
Buy the Full Report to Know More about the EPHB4 Pipeline Products
| Key Therapy Areas | · Oncology
· Genetic Disorders · Infectious Disease |
| Key Indications | · Non-Small Cell Lung Cancer
· Bile Duct Cancer (Cholangiocarcinoma) · Bladder Cancer · Colorectal Cancer · Gallbladder Cancer |
| Key Mechanisms of Action | · Ephrin Type B Receptor 4 Inhibitor |
| Key Routes of Administration | · Intravenous
· Intravesical · Oral |
| Key Molecule Types | · Small Molecule
· Fusion Protein · Synthetic Peptide |
| Leading Companies | · Kadmon Holdings Inc
· VasGene Therapeutics Inc |
| Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
EPHB4 Pipeline Products Segmentation by Therapy Areas
The key therapy areas associated with EPHB4 drugs in development are oncology, genetic disorders, and infectious diseases. The oncology therapy area had the highest share among EPHB4 drugs in development in 2022.
EPHB4 Pipeline Products Analysis by Therapy Areas, 2022 (%)
Buy the Full Report for More Therapy Area Insights into the EPHB4 Pipeline Products
EPHB4 Pipeline Products Segmentation by Indications
A few of the key indications for EPHB4 drug application include non-small cell lung cancer, bile duct cancer (cholangiocarcinoma), bladder cancer, colorectal cancer, and gallbladder cancer. Ephrin type B receptor 4 drugs had the highest number of products in development for non-small cell lung cancer in 2022.
EPHB4 Pipeline Products Analysis by Indications, 2022 (%)
Buy the Full Report for More Indication Insights into EPHB4 Pipeline Products
EPHB4 Pipeline Products Segmentation by MoA and Molecule Types
The only mechanism of action in EPHB4 drugs in development is Ephrin Type B Receptor 4 Inhibitor. The key molecule types associated with EPHB4 pipeline drugs are small molecule, fusion protein, and synthetic peptide. Among them, small molecule had the highest number in the pipeline in 2022.
EPHB4 Pipeline Products Analysis by Molecule Types, 2022 (%)
Buy the Full Report for More MoA and Molecule Type Insights into EPHB4 Pipeline Products
EPHB4 Pipeline Products Segmentation by Routes of Administration
The EPHB4 drugs can be administered by intravenous, intravesical, and oral methods. Intravenous and intravesical methods were equally preferred for EPHB4 drug administration in 2022.
EPHB4 Pipeline Products Analysis by Routes of Administration, 2022 (%)
Buy the Full Report for More RoA Insights into EPHB4 Pipeline Products
EPHB4 Pipeline Products - Competitive Landscape
VasGene Therapeutics Inc. had the highest number of products in the EPHB4 pipeline in 2022
The leading companies associated with EPHB4 pipeline products are:
- Kadmon Holdings Inc
- VasGene Therapeutics Inc
VasGene Therapeutics Inc.: VasGene is headquartered in Los Angeles, California, the US. It is a biotechnology company that discovers, develops, and commercializes therapeutics based on the understanding of vascular biology and cancer biology. VasGene’s products are used in treating cancer, AMD, and diabetic eye. It markets its products through its network of distributors across the world. The company provides the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics.
EPHB4 Pipeline Products Analysis by Companies, 2022 (%)
Buy the Full Report for More Company Insights into EPHB4 Pipeline Products
EPHB4 Pipeline Products - Featured News
13th November 2017: Kadmon Holdings, Inc. announced that the first patient was dosed in a Phase 2 clinical trial of tesevatinib in autosomal dominant polycystic kidney disease (ADPKD). Tesevatinib is the company’s tyrosine kinase inhibitor.
Buy the Full Report to Know More Featured News about EPHB4 Pipeline Products
Segments Covered in the Report
EPHB4 Pipeline Products Therapy Area Outlook (2022)
- Oncology
- Genetic Disorders
- Infectious Diseases
EPHB4 Pipeline Products Indication Outlook (2022)
- Non-Small Cell Lung Cancer
- Bile Duct Cancer (Cholangiocarcinoma)
- Bladder Cancer
- Colorectal Cancer
- Gallbladder Cancer
EPHB4 Pipeline Products MoA Outlook (2022)
- Ephrin Type B Receptor 4 Inhibitor
EPHB4 Pipeline Products RoA Outlook (2022)
- Intravenous
- Intravesical
- Oral
EPHB4 Pipeline Products Molecule Type Outlook (2022)
- Small Molecule
- Fusion Protein
- Synthetic Peptide
Scope
The report provides:
- A snapshot of the global therapeutic landscape of Ephrin Type B Receptor 4.
- Reviews of targeted therapeutics for Ephrin Type B Receptor 4 by companies and universities/research institutes. The review is based on information derived from company and industry-specific sources.
- Information about pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Key players involved in Ephrin Type B Receptor 4 therapeutics and enlist all their major and minor projects.
- Assessment of Ephrin Type B Receptor 4 therapeutics based on their drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Ephrin Type B Receptor 4.
Reasons to Buy
- Procure strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading therapy area in the EPHB4 drugs in development in 2022?
The oncology therapy area had the highest share among EPHB4 drugs in development in 2022.
-
Which was the leading indication in the EPHB4 drugs in development in 2022?
Ephrin type B receptor 4 drugs had the highest number of products in development for non-small cell lung cancer in 2022.
-
Which was the leading RoA for the EPHB4 drugs in development in 2022?
Intravenous and intravesical methods were equally preferred for EPHB4 drug administration in 2022.
-
Which was the leading molecule type for the EPHB4 drugs in development in 2022?
Small molecule was the leading molecule type for the EPHB4 drugs in development in 2022.
-
Which are the leading companies associated with EPHB4 drugs in development?
The leading companies associated with the EPHB4 pipeline products are Kadmon Holdings Inc and VasGene Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports